Vandetanib-eluting beads - BTG

Drug Profile

Vandetanib-eluting beads - BTG

Alternative Names: Vandetanib-eluting radiopaque beads

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BTG; Centre Hospitalier Universitaire Vaudois
  • Developer BTG; UCL Cancer Institute
  • Class Antineoplastics; Bromobenzenes; Fluorobenzenes; Piperidines; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; Proto oncogene protein c ret inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Colorectal cancer; Liver cancer

Most Recent Events

  • 10 Oct 2017 Preclinical trials in Colorectal cancer in United Kingdom before October 2017 (Intra-arterial)
  • 09 Oct 2017 Clinical trials in Colorectal cancer (Metastatic disease) (Intra-arterial) in United Kingdom
  • 09 Oct 2017 Clinical trials in Liver cancer (Second-line therapy or greater) (Intra-arterial) in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top